AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02959775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg dose hepatitis B vaccine
Description: three-dose, 20 µg per dose
Study NCT02067780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: One tablet per day for 7days.
Study NCT04996602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0 GBq of 177Lu-EB-PSMA
Description: Patients were intravenous administrated with the dose about 2.0 GBq (55 mCi) of 177Lu-EB-PSMA every 8 weeks (±1 week) for a maximum of 3 cycles.
Study NCT01268930 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar electrocautery for ovarian hemostasis
Description: after surgical excision of ovarian endometrioma with cyst wall, bipolar electrocoagulation is used to control of bleeding.
Study NCT03202381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix (Firmagon®) will be administered as a subcutaneous injection in the abdominal region every 28 days, in according to the following schedule:~* Starting dose: 240 mg administered as two consecutive subcutaneous injections of 120 mg each (2 x 3 mL injections).~* Maintenance dose: 80 mg administered as one subcutaneous injection of 80 mg (1 x 4 mL injection).~Treatment will be continued till clinically indicated or till disease progression.
Study NCT03706118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: At month 0, 12, 24 and 36 participants will be examined by quantitative magnetic resonance imaging of brain, cervical and part of thoracic spine.
Study NCT03684486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation by effort
Study NCT01552564 — intervention group
Intervention type: PROCEDURE
Intervention: Index of microvascular resistance
Study NCT01552564 — intervention group
Intervention type: OTHER
Intervention: Cardiac magnetic resonance
Study NCT01552564 — intervention group
Intervention type: OTHER
Intervention: Blood markers
Study NCT01005342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oat bran
Description: 82 g oat bran was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12.6 g total fiber).
Study NCT01005342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spray-dried oat drink
Description: 62 g spray-dried oat drink was added to 250 ml blackcurrant beverage with pulp to give 2.7 g soluble fiber (3.3 g total fiber).
Study NCT01005342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye bran
Description: 31 g rye bran was added to 250 ml blackcurrant beverage with pulp to give 1.7 g soluble fiber (12 g total fiber).
Study NCT01005342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar beet fiber
Description: 19 g sugar beet fiber was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12 g total fiber).
Study NCT01268930 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemostatic matrix (FloSeal)
Description: after surgical excision of ovarian endometrioma with cyst wall, hemostatic matrix is administered to the bed of cyst for 2-3 minutes to control of bleeding. Then, area is rinsed and hemostasis is checked.
Study NCT03689374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subjects will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly (OW) with a dose of 0.25 mg. The dose should be increased after four weeks to 0.5 mg semaglutide. After 4 more weeks the dose can be increased to 1.0 mg semaglutide if the study doctor decides and further dose adjusted throughout the study.
Study NCT03689374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Subjects should initiate treatment with 4U of Insulin aspart (s.c. injections) before each main meal, three times daily (TID). The dose will be adjusted individually based on pre-prandial and bedtime self measured plasma glucose (SMPG) from the preceding 3 days
Study NCT03689374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine U100
Description: Run-in period: Subjects will receive s.c. injections of IGlar U100 OD in accordance with the approved local label of IGlar U100. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.0-6.9 mmol/L)
Study NCT03689374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine U100
Description: Run-in period: Subjects will receive s.c. injections of IGlar U100 OD in accordance with the approved local label of IGlar U100. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.0-6.9 mmol/L)
Study NCT02254967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Description: oral tablets administered in an extended pulsed regimen
Study NCT02254967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: oral capsule
Study NCT01680159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650
Study NCT02780453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure dressing
Study NCT02780453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard wound dressing
Study NCT01703507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01005342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixture of fiber
Description: 38 g spray-dried oat drink, 30 g rye bran and 6 g sugar beet fiber were added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (18 g total fiber).
Study NCT01005342 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No fiber was added to control meal (250 g black-currant beverage)
Study NCT02805426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT02805426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02805426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Study NCT02805426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study NCT00000431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDGF-B/Ad5
Description: This is a dose finding study to evaluate the safety of a single injection of PDGF dna in an adenoviral vector.
Study NCT03764072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150
Description: Capsules for oral administration.
Study NCT01703507 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiation Therapy (WBRT)
Description: Undergo WBRT
Study NCT01703507 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Undergo SRS
Study NCT02949323 — intervention group
Intervention type: OTHER
Intervention: urinary stone
Description: patients of group one have urinary stones
Study NCT00909727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150-mg tablet given orally q12h for up to 48 weeks
Study NCT00909727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet given orally q12h for up to 48 weeks
Study NCT02450565 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Study NCT02748226 — intervention group
Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: endovascular treatment
Study NCT00760877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Supplied in 200 mg capsules
Study NCT00760877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Supplied in 100 mg and 400 mg capsules
Study NCT03950596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute resistant load exercises
Description: Leg bench and leg press acute resistant load exercises~Leg-bench and leg-press acute resistant load exercises
Study NCT03950596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Background Questionnaire
Description: Background questionnaire will be filled out by participants
Study NCT00942461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic colectomy
Description: Laparoscopic colectomy. Epidural anaesthesia used
Study NCT00942461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open colectomy
Description: Open colectomy. Epidural anaesthesia used
Study NCT00492206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. Subjects will receive cetuximab from week 0 through week 26.
Study NCT02823899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HL-OCV
Description: Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
Study NCT02823899 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol
Description: The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
Study NCT03764072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral administration.
Study NCT03950596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Questionnaire
Description: Pain questionnaire regarding pain in the knee during previous 3 months
Study NCT04012684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: For one-session rTMS, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz, 100% resting motor threshold TMS pulses. The inter-train interval is 26 seconds.
Study NCT04012684 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: For one-session sham stimulation, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz sham pulses. The inter-train interval is 26 seconds.
Study NCT02355028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHA510 ophthalmic suspension
Study NCT02355028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LHA510 vehicle
Description: Inactive ingredients used as a placebo comparator
Study NCT02355028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab ophthalmic solution
Description: For intravitreal (IVT) injection
Study NCT02355028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranibizumab ophthalmic solution
Description: For intravitreal (IVT) injection
Study NCT00724581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
Study NCT01298505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654764 2.5mg plus fexofenadine 60mg
Description: PF-03654764 2.5mg plus fexofenadine 60mg twice daily for 7 days
Study NCT01298505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654764 5mg plus fexofenadine 60mg
Description: PF-03654764 5mg plus fexofenadine 60mg twice daily for 7 days
Study NCT01298505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo given twice daily for 7 days
Study NCT03438695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motorized Spiral Enteroscopy
Description: Motorized Spiral endoscope will be inserted and advanced with the assistance of motorized clockwise spiral rotation, After reaching the cecum or if no further advancement of the endoscope can be achieved depth of insertion required for patient treatment or diagnosis, the endoscope will be withdrawn using motorized counter-clockwise spiral rotation, also controlled by the foot pedal. If no total enteroscopy was achieved, a submucosal ink dye injection is performed as an endoscopically visible marker of the maximum insertion depth. A retrograde peranal enteroscopy is then performed on one of the following days.
Study NCT04762693 — intervention group
Intervention type: DEVICE
Intervention: Hyfe cough tracker
Description: A mobile app that runs in the background of smartphones and detects putative cough sounds.
Study NCT00652223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT005-AllQbG10
Description: Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT
Study NCT03117348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: Patients in Gradual Goal-dose EN group will receive increased calories gradually by EN and will reach the 80% of target energy by EN at day 8 while patients in immediate Goal-dose EN group will receive 100% of target energy by EN at day 3 after abdominal surgery. Both of the two group will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital, whichever arrives first.
Study NCT02129101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV
Study NCT02129101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT02129101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02129101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02129101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonidegib
Description: Given PO
Study NCT03917784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Oral supplementation with curcumin 500 mg oral dosing for 3 months
Study NCT03917784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Description: Oral supplementation with starch 500 mg oral dosing for 3 months
Study NCT02461095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Impairment based approach
Description: This intervention will consist of exercise, mechanics training, education, manual therapy and modalities. The treatment will address the impairments found during the evaluation. This approach is a typical individualized physical therapy treatment approach.
Study NCT02461095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFPS Algorithm approach
Description: Physical Therapy treatment for Patellofemoral Pain Syndrome based upon a treatment algorithm that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patient with the goals of low fear avoidance beliefs, flexibility, body mechanics, and strength and are performed in a sequential manner
Study NCT01507636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: Occupational therapy using a special arm function training.
Study NCT01507636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy for arm force training.
Study NCT00667472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
Study NCT00667472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser
Description: Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
Study NCT03995784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor IX variant
Description: Single intravenous injection of CB2679d/Dalcinonacog alfa
Study NCT03995784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor IX variant
Description: Daily subcutaneous injections of CB2679d/Dalcinonacog alfa for 28 days
Study NCT03018964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Solo surgery
Description: Solo surgery using a camera scope holder in single incision laparoscopic cholecystectomy
Study NCT03018964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operation with a camera operator in SILC
Description: conventional single incision laparoscopic cholecystectomy with a scopist
Study NCT03784040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTSGC-A24
Description: OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
Study NCT03784040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
Study NCT03784040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
Study NCT03537079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypoxia air
Description: Normobaric hypoxia is generated by adding azote in normal air to decrease the oxygen availability.
Study NCT03537079 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hypoxia air
Description: Normobaric hypoxia is generated by adding azote in normal air to decrease the oxygen availability.
Study NCT03468959 — intervention group
Intervention type: BEHAVIORAL
Intervention: Maternal Supplemental PUFA Intake
Description: Maternal Supplemental PUFA Intake included sources from the questionnaires and plasma
Study NCT00970541 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamon Supplementation
Description: 1, 3, or 6g of cinnamon per day for 40 days
Study NCT00970541 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (wheat flour)
Description: 1, 3, or 6g of placebo per day for 40 days
Study NCT05541562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: clinical laboratory tests, and imaging characteristics
Description: Data included the demographic status, etiology of the liver disease, clinical laboratory tests, and imaging characteristics. Clinical laboratory tests included D-dimer, activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin III, international normalized ratio (INR), thrombin time (TT), albumin (Alb), serum creatinine, hemoglobin, platelet count, white blood cell count, neutrophil count, lymphocyte count, monocyte count, model for end-stage liver disease (MELD) score, and Child-Pugh score. Imaging characteristics included splenic vein diameter, splenic vein velocity, portal vein diameter, and portal vein velocity.
Study NCT01738880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVV
Description: During the surgery, patients in group S receive additional fluids (400 ml of normal saline or 200 ml of colloid) when SVV is less than 13.
Study NCT01738880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVP
Description: Patients in group C receive additional fluids (400 ml of normal saline or 200 ml of colloid) when CVP is less 8 during the surgery.
Study NCT02537639 — intervention group
Intervention type: DEVICE
Intervention: Transesophageal echocardiography simulator
Study NCT03988075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen and hydrocodone based pain control
Description: Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
Study NCT03988075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetaminophen and ibuprofen based pain control
Description: Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
Study NCT00834808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.